Nell’ambito delle nuove terapie per il trattamento delle pazienti con cancro della mammella metastatico HER2+, emergono gli antibody drug conjugate. Di questa classe di farmaci e degli studi in corso in Italia abbiamo chiesto notizie a Giampaolo Bianchini (Responsabile Unità Tumori della Mammella UO Medicina Oncologica – Ospedale San Raffaele, Milano) nel corso dell’ultimo congresso AIOM.

BIBLIOGRAFIA

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1 – DS8201-A-U301 (DESTINY-B02) https://bit.ly/2O8F4G9

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane – DS8201-A-U302 (DESTINY-B03) https://bit.ly/2qL5JRw